Relationship Between Tumor-associated Immune Infiltrate and P16 Staining over Clinicopathological Features in Acral Lentiginous Melanoma

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2019 Feb 20

PMID 30778854

Citations 15

Authors

C A Castaneda

M Castillo

C Torres-Cabala

L A Bernabe

S Casavilca

V Villegas

J Sanchez

M de la Cruz

J Dunstan

J M Cotrina

H L Gomez

C Chavez

M P Landa-Baella

K Tello

B F Felix

J Abugattas

Affiliations

Soon will be listed here.

Abstract

Purpose: This study aims to evaluate the association between composition of tumor-infiltrating lymphocytes (TIL) and expression of p16 in acral lentiginous melanoma (ALM), and their impact on prognosis.

Materials And Methods: A cohort of 148 surgical pathology specimens of ALM was studied. TIL were evaluated by immunohistochemical detection of CD3 and CD8, along with CD20, CD4, CD68, and CD163 in a subset of 43 cases. p16 protein expression was also investigated in all the cases.

Results: The median age was 66 years, median Breslow thickness was 6.0 mm, grade III TIL was found in 28.4% and lymph nodes were involved in 54.2%. Breslow thickness (p < 0.001), stage I-II (p < 0.001), negative lymph nodes (p < 0.001) and < 10% p16 (p = 0.01) were associated with longer survival. Grade III of TIL was associated with thinner Breslow thickness (p = 0.008) and lower mitosis (p = 0.047). A higher density of CD3 TIL was associated with male gender (p = 0.008), thinner Breslow thickness (p = 0.047), negative lymph node (p = 0.031), early stage (p = 0.046), and p16 nuclear expression of > 10% (p = 0.045). Higher CD8 TIL was associated with > p16 (p = 0.03). Survival analysis found that longer survival had a trend to be associated with high TIL (p = 0.090). Levels of CD3+ and CD8+ cells were correlated with those of CD4+, CD20+, CD68+ and CD163+ immune cells.

Conclusions: Higher levels of TIL tend to be associated with better overall survival in ALM. Loss of expression of p16 is associated with lower levels of CD3+ and CD8+ TIL, indicating a probable relationship between p16 and TIL immune response in ALM .

Citing Articles

A Narrative Review of the Evolution of Diagnostic Techniques and Treatment Strategies for Acral Lentiginous Melanoma.

Choi M, Choi E, Jung J, Lee W, Jo Y, Won C Int J Mol Sci. 2024; 25(19).

PMID: 39408752 PMC: 11477219. DOI: 10.3390/ijms251910414.

CD8-Lymphocytic Phenotype Significance in Primary Multiple and Familial Melanoma with Various CDKN2A Mutational Status.

Bosoteanu L, Gheorghe E, Aschie M, Cozaru G, Deacu M, Baltatescu G Medicina (Kaunas). 2023; 59(12).

PMID: 38138255 PMC: 10744472. DOI: 10.3390/medicina59122151.

Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy.

Nguyen N, Wan G, Ugwu-Dike P, Alexander N, Raval N, Zhang S J Am Acad Dermatol. 2023; 88(6):1308-1316.

PMID: 36828138 PMC: 10260279. DOI: 10.1016/j.jaad.2023.02.014.

Advanced Acral Melanoma Therapies: Current Status and Future Directions.

Zhang Y, Lan S, Wu D Curr Treat Options Oncol. 2022; 23(10):1405-1427.

PMID: 36125617 PMC: 9526689. DOI: 10.1007/s11864-022-01007-6.

Clinical features, molecular pathology, and immune microenvironmental characteristics of acral melanoma.

Gui J, Guo Z, Wu D J Transl Med. 2022; 20(1):367.

PMID: 35974375 PMC: 9382740. DOI: 10.1186/s12967-022-03532-2.

References

Tuthill R, Unger J, Liu P, Flaherty L, Sondak V . Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am J Clin Pathol. 2002; 118(4):504-11. DOI: 10.1309/WBF7-N8KH-71KT-RVQ9. View

Piras F, Colombari R, Minerba L, Murtas D, Floris C, Maxia C . The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer. 2005; 104(6):1246-54. DOI: 10.1002/cncr.21283. View

Mihic-Probst D, Mnich C, Oberholzer P, Seifert B, Sasse B, Moch H . p16 expression in primary malignant melanoma is associated with prognosis and lymph node status. Int J Cancer. 2005; 118(9):2262-8. DOI: 10.1002/ijc.21608. View

Sato E, Olson S, Ahn J, Bundy B, Nishikawa H, Qian F . Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005; 102(51):18538-43. PMC: 1311741. DOI: 10.1073/pnas.0509182102. View

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C . Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313(5795):1960-4. DOI: 10.1126/science.1129139. View

Piersma S, Jordanova E, van Poelgeest M, Kwappenberg K, van der Hulst J, Drijfhout J . High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res. 2007; 67(1):354-61. DOI: 10.1158/0008-5472.CAN-06-3388. View

Robinson B, Sica G, Liu Y, Rohan T, Gertler F, Condeelis J . Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination. Clin Cancer Res. 2009; 15(7):2433-41. PMC: 3156570. DOI: 10.1158/1078-0432.CCR-08-2179. View

Jensen T, Schmidt H, Moller H, Hoyer M, Maniecki M, Sjoegren P . Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol. 2009; 27(20):3330-7. DOI: 10.1200/JCO.2008.19.9919. View

Balch C, Gershenwald J, Soong S, Thompson J, Atkins M, Byrd D . Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009; 27(36):6199-206. PMC: 2793035. DOI: 10.1200/JCO.2009.23.4799. View

10.

Romagosa C, Simonetti S, Lopez-Vicente L, Mazo A, LLeonart M, Castellvi J . p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene. 2011; 30(18):2087-97. DOI: 10.1038/onc.2010.614. View

11.

Jensen T, Schmidt H, Moller H, Donskov F, Hoyer M, Sjoegren P . Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer. 2011; 118(9):2476-85. DOI: 10.1002/cncr.26511. View

12.

Storr S, Safuan S, Mitra A, Elliott F, Walker C, Vasko M . Objective assessment of blood and lymphatic vessel invasion and association with macrophage infiltration in cutaneous melanoma. Mod Pathol. 2011; 25(4):493-504. PMC: 3318158. DOI: 10.1038/modpathol.2011.182. View

13.

Erdag G, Schaefer J, Smolkin M, Deacon D, Shea S, Dengel L . Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 2012; 72(5):1070-80. PMC: 3306813. DOI: 10.1158/0008-5472.CAN-11-3218. View

14.

Azimi F, Scolyer R, Rumcheva P, Moncrieff M, Murali R, McCarthy S . Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol. 2012; 30(21):2678-83. DOI: 10.1200/JCO.2011.37.8539. View

15.

Clark Jr W, Elder D, Guerry 4th D, Braitman L, Trock B, Schultz D . Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989; 81(24):1893-904. DOI: 10.1093/jnci/81.24.1893. View

16.

Castaneda C, Torres-Cabala C, Castillo M, Villegas V, Casavilca S, Cano L . Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America. Clin Transl Oncol. 2017; 19(12):1478-1488. DOI: 10.1007/s12094-017-1685-3. View

17.

Clemente C, Mihm Jr M, Bufalino R, Zurrida S, Collini P, Cascinelli N . Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996; 77(7):1303-10. DOI: 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5. View